帕金森异动高热综合征1例并文献复习

doi:10.3969/j.issn.1003-9198.2025.11.024

[1] GIL-NAVARRO S, GRANDAS F. Dyskinesia-hyperpyrexia syndrome: another Parkinson’s disease emergency[J]. Mov Disord, 2010, 25(15): 2691-2692.
[2] DU X, WANG X, GENG X. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease triggered by overdose of levodopa - a case report and literature review[J]. Front Neurol, 2024, 14: 1323717.
[3] RAJAN R, KRISHNAN S, KESAVAPISHARADY K K, et al. Malignant subthalamic nucleus-deep brain stimulation withdrawal syndrome in Parkinson’s disease[J]. Mov Disord Clin Pract, 2016, 3(3): 288-291.
[4] PRANGE S, DANAILA T, LAURENCIN C, et al. Age and time course of long-term motor and nonmotor complications in Parkinson disease[J]. Neurology, 2019, 92(2): e148-e160.
[5] WANG M, WANG W, GAO Z, et al. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: a systematic review[J]. Clin Auton Res, 2021, 31(4): 529-542.
[6] BLANCHET P J, FANG J, HYLAND K, et al. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study[J]. Neurology, 1999, 53(1): 91-95.
[7] ZAPPIA M, CRESCIBENE L, ARABIA G, et al. Body weight influences pharmacokinetics of levodopa in Parkinson’s disease[J]. Clin Neuropharmacol, 2002, 25(2): 79-82.
[8] SARCHIOTO M, RICCHI V, MELIS M, et al. Dyskinesia-hyperpyrexia syndrome in Parkinson’s disease: a heat shock-related emergency?[J]. Mov Disord Clin Pract, 2018, 5(5): 534-537.
[9] LIN M T, HO M T, YOUNG M S. Stimulation of the nigrostriatal dopamine system inhibits both heat production and heat loss mechanisms in rats[J]. Naunyn Schmiedebergs Arch Pharmacol, 1992, 346(5): 504-510.
[10] LIN M T, CHANDRA A, TSAY B L, et al. Hypothalamic and striatal dopamine receptor activation inhibits heat production in the rat[J]. Am J Physiol, 1982, 242(5): R471-R481.
[11] DE FUENTE-FERNÁNDEZ R. Presynaptic mechanisms of motor complications in Parkinson disease[J]. Arch Neurol, 2007, 64(1): 141-143.
[12] LINAZASORO G. Pathophysiology of motor complications in parkinson disease: postsynaptic mechanisms are crucial[J]. Arch Neurol, 2007, 64(1): 137-140.
[13] BAEK M S, LEE H W, LYOO C H. A patient with recurrent dyskinesia and hyperpyrexia syndrome[J]. J Mov Disord, 2017, 10(3): 154-157.
[14] NAKAMURA K. Central circuitries for body temperature regulation and fever[J]. Am J Physiol Regul Integr Comp Physiol, 2011, 301(5): R1207-R1228.
[15] TORU M, MATSUDA O, MAKIGUCHI K, et al. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs[J]. J Nerv Ment Dis, 1981, 169(5): 324-327.
[16] BOYER E W, SHANNON M. The serotonin syndrome[J]. N Engl J Med, 2005, 352(11): 1112-1120.
[17] LYOO C H, LEE M S. Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson’s disease[J]. J Neurol, 2011, 258(10): 1893-1894.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	YUAN Lili, ZOU Qiangwei. Advances in multi-omics research on Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(10): 1003-1008.
[2]	WANG Miaohui, FAN Xuhang, CHEN Siyao, YANG Xiaojuan. Research progress on the correlation between Alzheimer’s disease and osteoporosis [J]. Practical Geriatrics, 2025, 39(9): 937-941.
[3]	WANG Yun, FU Liping. Significance of retinal structural and functional changes in the diagnosis of Alzheimer’s disease in high-altitude regions [J]. Practical Geriatrics, 2025, 39(5): 461-465.
[4]	LAI Shuyuan, YU Shuping, YAN Lirong, GUI Qiliang, CHEN Feng. Correlation between cognitive impairment and ability of the elderly in nursing institution [J]. Practical Geriatrics, 2025, 39(4): 377-381.
[5]	ZHOU Xiang, XIANG Xiaoping. Effects of different-intensity phototherapy on sleep quality in elderly patients with Parkinson’s disease and insomnia [J]. Practical Geriatrics, 2025, 39(4): 401-405.
[6]	WANG Yan, XU Jie, GU Xiaoping. Research advances on association between fatty acid metabolism and Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(4): 415-419.
[7]	LIN Xiaoqi, ZHAO Xinjing, WU Yashuang, ZHAO Wei, CHEN Chen, GAO Tianyu, ZHOU Guoyu. Advances of the mechanisms of gender differences in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(4): 420-425.
[8]	JING Chaonan, ZHANG Guanqun, WANG Jiangbo. Correlation of serum levels of sclerostin and 25 hydroxyvitamin D with MMSE score in patients with Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(3): 268-271.
[9]	LIU Shu. A review of impact of cognitive reserve on cognitive function [J]. Practical Geriatrics, 2025, 39(3): 308-311.
[10]	Expert Guidance Writing Group for the Levodopa/Carbidopa/Entacapone in Early Parkinson's Diseas (CHEN Ling, CHENG Oumei, CUI Guiyun, HUANG Wei, LIU Chunfeng, LIU Weiguo, LIU Zhenguo, MAO Chengjie, MAO Wei, WU Yuncheng, ZHU Xiaodong, ZHENG Huifen, CHENG Xiaoyu). Expert Advice on the Clinical Application of Levodopa/Carbidopa/Entacapone at Early Stage of Parkinson's Disease [J]. Practical Geriatrics, 2025, 39(3): 325-330.
[11]	XIN Mengfan, FENG Meijiang. Advance in the diagnosis and treatment of Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(2): 121-126.
[12]	MEI Kele, GAO Langli, LIU Yadong, LYU Juan, YUE Jirong. Reliability and validity of the Chinese version of the delirium screening scale in elderly inpatients [J]. Practical Geriatrics, 2025, 39(2): 171-174.
[13]	WU Jinli, YANG Xiaojuan. Research progress of calprotectin S100A8/S100A9 in Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(2): 197-201.
[14]	MA Xiaoting, LIU Shanwen, YAO Linlin, BAO Runying, LI Yifeng, YANG Yifan, HU Hua. Mechanism of inflammaging in the progression of Alzheimer's disease [J]. Practical Geriatrics, 2025, 39(2): 202-206.
[15]	WANG Siya, YIN Shi. Effects of environmental exposure on cognitive impairment [J]. Practical Geriatrics, 2025, 39(1): 22-25.